1. Home
  2. LXEO vs PROC Comparison

LXEO vs PROC Comparison

Compare LXEO & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LXEO
  • PROC
  • Stock Information
  • Founded
  • LXEO 2017
  • PROC 1976
  • Country
  • LXEO United States
  • PROC Luxembourg
  • Employees
  • LXEO N/A
  • PROC N/A
  • Industry
  • LXEO
  • PROC Biotechnology: Pharmaceutical Preparations
  • Sector
  • LXEO
  • PROC Health Care
  • Exchange
  • LXEO Nasdaq
  • PROC Nasdaq
  • Market Cap
  • LXEO 252.4M
  • PROC 203.1M
  • IPO Year
  • LXEO 2023
  • PROC N/A
  • Fundamental
  • Price
  • LXEO $6.14
  • PROC $2.55
  • Analyst Decision
  • LXEO Strong Buy
  • PROC
  • Analyst Count
  • LXEO 5
  • PROC 0
  • Target Price
  • LXEO $23.80
  • PROC N/A
  • AVG Volume (30 Days)
  • LXEO 274.8K
  • PROC 136.7K
  • Earning Date
  • LXEO 12-31-2024
  • PROC 02-15-2025
  • Dividend Yield
  • LXEO N/A
  • PROC N/A
  • EPS Growth
  • LXEO N/A
  • PROC N/A
  • EPS
  • LXEO N/A
  • PROC 0.52
  • Revenue
  • LXEO N/A
  • PROC $414,096,000.00
  • Revenue This Year
  • LXEO N/A
  • PROC $5.54
  • Revenue Next Year
  • LXEO N/A
  • PROC $8.54
  • P/E Ratio
  • LXEO N/A
  • PROC $4.87
  • Revenue Growth
  • LXEO N/A
  • PROC N/A
  • 52 Week Low
  • LXEO $5.77
  • PROC $0.50
  • 52 Week High
  • LXEO $22.33
  • PROC $4.95
  • Technical
  • Relative Strength Index (RSI)
  • LXEO 35.77
  • PROC 57.57
  • Support Level
  • LXEO $6.78
  • PROC $2.40
  • Resistance Level
  • LXEO $7.40
  • PROC $3.78
  • Average True Range (ATR)
  • LXEO 0.66
  • PROC 0.46
  • MACD
  • LXEO -0.13
  • PROC 0.09
  • Stochastic Oscillator
  • LXEO 1.34
  • PROC 55.63

About LXEO Lexeo Therapeutics Inc.

Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.

About PROC Procaps Group S.A.

Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.

Share on Social Networks: